Legend Innovation Life Science Fund has announced it will invest up to $50 million in Mid-Atlantic BioTherapeutics, a clinical-stage biotech company based in Pennsylvania. This funding will help support the company’s current clinical trials, research efforts, and regulatory objectives. The first part of this investment is expected to be received in the third quarter of 2025, marking a key development in the company’s expansion.
Health Technology Insights: Dr. Jerome Adams Joins Eko Health as Distinguished Medical Advisor
Mid-Atlantic BioTherapeutics plans to start a Phase 3 clinical trial for its leading treatment for viral encephalitis in 2026. Additionally, the company aims to grow its clinical pipeline using an AI-based platform that combines computational chemistry, structure analysis, and fragment-based drug discovery. MABT also intends to pursue a public listing through an IPO or a reverse merger within the next 18 months.
Dr. Syngbum Ben Kim, Chairman and Founder of Legend, stated, “Our commitment to advancing healthcare innovation is shown through this partnership with Mid-Atlantic BioTherapeutics. MABT’s scientific vision and strong leadership make them a great fit for our fund as we work to quickly turn cutting-edge research into real treatments for patients.”
Health Technology Insights: Viant and AdTegral Partner to Activate SMB Agencies and Brands
Dr. David Horn, CEO and Founder of Mid-Atlantic BioTherapeutics, added, “We are grateful for Legend’s confidence in our technology and mission. This strategic investment will allow us to speed up our programs focused on different aspects of anti-aging. With Legend’s support, we are well-positioned to accelerate initiatives that aim to extend both the length and quality of people’s lives.”
Legend Innovation Fund focuses on supporting biotech companies that use artificial intelligence to drive drug discovery and development, especially in the areas of anti-aging and regenerative medicine. The fund targets companies that are close to entering the public market, helping them achieve successful listings in the US. This partnership is expected to help bring forward innovative therapies that can have a major impact on patient care while also creating value for investors. Both organizations are excited about working together to develop groundbreaking treatments and set new standards for biotech innovation.
Health Technology Insights: OM1 Rheumatoid Arthritis Dataset Rated High Quality, Boosts AI Review Speed
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
